The $5 Billion Bet Isn't on Pipelines: The Core Logic of In Vivo CAR-T Lies in Solving Five Key Development Hurdles!
Undoubtedly, 2025 isThe Breakout Year for In Vivo CAR-T.
March,AstraZenecaAcquired EsoBiotec for $1 billion, gaining its lentiviral technology platform;
In June, AbbVie acquired Capstan for $2.1 billion, gaining access to Capstan’s core platform technologies, including targeted lipid nanoparticles (tLNP).
In August, Gilead’s Kite acquired Interius for $350 million, integrating Interius’s in vivo integration platform.
On the 10th of last month, BMS announced its intention to acquireOrbital Therapeutics，The core asset of the transaction is aIn Vivo CAR-TTherapy——OTX-201，The price is $1.5 billion in cash, making it this year’sMNCThe fourth M&A transaction in the in vivo CAR-T field further highlights the platform potential and market value of in vivo CAR-T.
Obviously,In Vivo CAR-TIt has become a fiercely contested battleground for multinational corporations (MNCs).The total value of the four M&A transactions approaches $5 billion. The core value of these deals lies not only in the pipeline assets themselves, but also in the cost optimization, improved product accessibility, and future market potential driven by these cutting-edge platforms and technologies.
Driven by the dual forces of policy incentives and clinical demand, in vivo CAR-T technology bypasses ex vivo manufacturing entirely, instead generating CAR-T cells directly within patients via delivery systems. This disruptive approach reduces production costs to 10% of those associated with traditional CAR-T therapies, significantly enhancing accessibility. Furthermore, mRNA delivery system-mediated in vivo CAR-T exhibits only transient expression in host cells, thereby mitigating potential genotoxicity and cytokine toxicity, making it particularly suitable for autoimmune diseases. Consequently, this has sparked a surge of interest among investors and multinational corporations (MNCs), with substantial capital investment validating the strong commercial prospects of in vivo CAR-T in the cell therapy sector.
Yet behind these opportunities, bottlenecks in R&D, delivery, CMC, clinical development, and regulatory approval remain formidable hurdles standing between companies and commercial success:
How to Reduce Toxic Side Effects Through Engineering Design
Insufficient Targeting of Solid Tumors and Strategies to Enhance the In Vivo Stability of mRNA
In vivo CAR-T, or “in situ generation,” precludes quality control of the cell product prior to infusion, necessitating the establishment of new quality monitoring metrics.
How to AvoidCarrier Immunogenicity
LNP-mRNA, Lentivirus, and AAV: What Are the Respective Advantages and Disadvantages of These Three Delivery Pathways?
How to Precisely Deliver CAR Genes to T Cells and Avoid Nonspecific Infection of Other Cells
How to EstablishIn Vivo CAR-TCritical Quality Attributes
How to Establish Stable and Reproducible Specifications and Release Testing Methods
How to Maintain Process and Efficacy Consistency During Process Scale-Up and Large-Scale Production
How to Rapidly and Effectively Explore in Clinical Trial DesignIn Vivo CAR-TSafe Dosage
How Can Product R&D and Clinical Teams Effectively Design Trials in the Face of Individual Variability and the Body’s “Black Box”?
It has also been observed from real-world clinical data thatIn Vivo CAR-TWhat Potential? What Risks?
In Vivo CAR-T falls within the intersection of gene therapy and cell therapy, lacking a mature regulatory pathway.
Current exploration is primarily focused on hematologic malignancies; efficacy and safety data for solid tumors and autoimmune diseases are limited, and additional clinical evidence is required to support regulatory filing applications.
Given the novelty of the technology and its substantial potential risks, regulatory agencies will exercise exceptional caution in their risk-benefit assessments. How should applicants respond?
.......
How to Crack the “Technical Code” of In Vivo CAR-T? From Target Screening to Process Optimization, and from Quality Control to Real-World Studies, How Can Key Points Across the Entire Workflow Be Precisely Managed? How Can Innovative Therapies Both Meet Regulatory Requirements and Truly Address Pain Points in Patient Accessibility?
「In Vivo Cell Therapy: Practical Training on Key Points Across the Entire Process of R&D, Delivery, CMC, Clinical Development, and Regulatory Registration」Rising to the Occasion! We have assembled a team of experts with extensive experience and profound understanding of in vivo CAR-T processes, analytics, quality control, manufacturing, and clinical applications. This program offers systematic knowledge acquisition and methodological mastery focusing on key areas such as delivery technologies, quality control and analytics, manufacturing controls and compliance, clinical trial design, and interpretation of clinical data. Leveraging real-world case studies, we help you solve real-world problems!
Training Overview
Training Name：In Vivo Cell Therapy: Practical Training on Key Points Across the Entire Process of R&D, Delivery, CMC, Clinical Development, and Regulatory Registration
Training Duration: December 20-21
Training Venue: Wuhan
Training Scale: Approximately 50 people
Organizer：CSGCT Alliance,VCBeat,Hubei Provincial Clinical Medical Center for Cell Therapy in Oncology
Co-Organizers: Biologics Circle, Antibody Circle
Scan the QR code above to register and secure your spot.
Training Outline
The complete course consists of 11 content modules and 24 class hours. There are 4 class hours per day, for a total of 6 days;The complete training program is divided into three sessions, each lasting two days, for a total of six days. It will be completed within 3–6 months.
Module 1: In VivoOrigins of CAR-T Technology and R&D Pain Points
Bottlenecks in Ex Vivo CAR-T Development: Prolonged Autologous Manufacturing Lead Time (16–33 Days), Risk of Allogeneic GvHD, and Toxicity Associated with Lymphodepleting Preconditioning Highlight the Need for In Vivo Technology Development
Evolution of In Vivo CAR-T R&D: The Technological Iteration Logic from “Simplified Manufacturing” to “Precision Delivery” and Then to “Multi-Domain Expansion”
Core R&D Objectives: Addressing the three key challenges of delivery efficiency, targeting specificity, and safety, and comparing the differences in R&D prioritization relative to ex vivo CAR-T therapies
Module 2: In VivoR&D Progress on Core CAR-T Delivery Platforms
LNP-mRNA Platform: Leveraging the mature manufacturing process of COVID-19 vaccines, transient expression (without genomic integration) reduces toxicity, while CD3/CD8-targeted modifications enhance transfection efficiency. Key R&D challenges include process complexity and off-target transfection in macrophages.
Polymer Nanoparticle Platforms: pH-Responsive Endosomal Escape Design of Cationic Vectors Such as PBAE, Advantages in Lyophilization Stability, the Need for Multiple Doses of mRNA, and the Risk of Insertional Mutagenesis Associated with DNA Transposons
Viral Vector Platforms: Long-term Expression and Insertional Mutagenesis Risks of Lentiviral Vectors (Nipah Virus Pseudotyped, DARPin-Targeted); Safety Advantages of AAV Episomal Forms and Their R&D Potential in CD4+ T Cell Diseases
Novel Vector Platforms: Precision Cell Editing with Cas9-EDVs (Targeting CD3/CD4/CD28) and Transient Membrane Expression of CAR Proteins via FuNVs; R&D Focus on In Vivo Anti-Tumor Efficacy Validation
Module 3:Non-In Vivo CAR Engineering of T Cells: R&D Exploration
Hydrogel and PBAE+RP-182 Peptide Reprogram M2 Macrophages: Activation of Infiltration and Phagocytic Function in Glioma and Pancreatic Cancer Models
CAR-NK Cells: R&D Bottlenecks Include Poor Persistence, Low Transduction Efficiency, and Dependence on IL-15 Cytokine Support; Current Directions for Optimization in Preclinical Studies
Other Cell Types: In Vivo Engineering Feasibility and R&D Value of NKT Cells and Neutrophils
Module 4:Design of Key Technical Indicators for In Vivo CAR-T Research and Development
Delivery System R&D Metrics: Targeting Efficiency (e.g., 30–50% transduction rate in CD8+ T cells), Vector Stability (in vivo half-life of 1–7 hours), and Scalability Feasibility (potential for repurposing existing COVID-19 vaccine manufacturing facilities)
Functional Assessment Metrics: Duration of CAR expression (e.g., LNP-mRNA maintaining anti-tumor efficacy for 90 days), in vivo expansion rate, and tumor homing efficiency (enrichment capacity in the solid tumor microenvironment [TME])
Safety Assessment Endpoints: Risk of Insertional Mutagenesis (Comparison of Integrating vs. Non-Integrating Vectors), Off-Target Effects (Transduction Rate in Non-Target Cells), Toxicity Reactions (Incidence of CRS/ICANS, Risk of Hepatotoxicity)
Module 5:In VivoR&D Expansion of CAR-T in Non-Oncology Fields
Autoimmune Diseases: R&D Progress of CAR-T Therapy Targeting CD19/BCMA/DSG3 to Eliminate Pathogenic B Cells in Systemic Lupus Erythematosus and Multiple Sclerosis
Infectious Diseases: Phase I/II Clinical Exploration of HIV gp120-Targeted CAR-T and Design of CD4+ T Cell Protection Mechanisms
Fibrotic Diseases: CD5-Targeted LNP Delivery of FAP-CAR mRNA Reduces Cardiac Fibrosis by 50% in Mouse Models, with R&D Focus on Specific Recognition of Activated Fibroblasts
Production and R&D: The "off-the-shelf" nature of in vivo technology simplifies quality control, whereas ex vivo autologous approaches require specialized facilities (high cost).
Efficacy R&D: In vivo technologies preserve immune function without the need for lymphodepletion and enable multi-target combination therapies; ex vivo autologous approaches demonstrate clear efficacy in hematologic malignancies but exhibit poor tumor homing in solid tumors.
Safety R&D: In vivo non-integrating vectors reduce long-term risks; ex vivo autologous viral integration carries a risk of mutation; in vivo applications require attention to vector-mediated inflammatory responses.
Module 7: In VivoCore R&D Bottlenecks and Solutions for CAR-T
Low Targeted Delivery Efficiency: Multi-target modification (e.g., lentiviral vectors combined with CD80/CD58 co-stimulatory ligands), local microenvironment modulation via biological scaffolds (alginate/collagen scaffolds for T-cell recruitment)
# Limited Efficacy of Solid Tumor Treatments: Combined with ECM-degrading enzymes to improve the TME, synergizing with PD-1 inhibitors/radiotherapy/oncolytic viruses, data showing increased tumor regression rates in preclinical models
Safety Risks: Development of safety switch systems (to address T-cell exhaustion caused by persistent CAR-T cell survival); vector engineering for patients with pre-existing antibodies (to avoid immune clearance)
Industrialization Bottlenecks: Scalable vector production (insufficient AAV yield), cost control (cost differences between ex vivo autologous and in vivo technologies)
Immunotherapy Combination: Synergizes with PD-1/PD-L1 inhibitors to activate T cells and reduce immunosuppression in the TME
Drug Combination: Chemotherapy Pretreatment Improves TME; Small-Molecule Drugs Enhance CAR-T Proliferation
Gene Union: Co-delivery of siRNA to silence the PD-1 gene (enhancing T-cell activity) and cytokine genetic engineering (improving persistence)
Other Combinations: Vaccine antigens synergistically enhance immune responses; oncolytic viruses combinatorially disrupt tumor architecture
Module 9: In VivoDesign of the Clinical Translation Pathway for CAR-T Therapy
Preclinical Study Design: Selection of Humanized Mouse Models (e.g., NSG Mice for Lymphoma Clearance Assessment) and Validation in Non-Human Primate Models (76-Day Data on B-Cell Depletion Using Lentiviral Vectors)
Clinical Trial Design: Indication Prioritization (Refractory Hematologic Malignancies → Superficial Solid Tumors → Deep-Seated Solid Tumors), Dose Escalation Scheme (Avoiding Vector Dose-Limiting Toxicity), and Safety Monitoring Plan (Long-Term Follow-Up for Insertional Mutagenesis and Secondary Malignancy Risks)
Regulatory Considerations: Adaptability of the Existing CAR-T Regulatory Framework, Special Approval Pathways for Non-integrating Vectors, and Key Focus Areas of Ethical Review (Risk Disclosure in Informed Consent)
Module 10: Future R&D Directions and Industry-Academia-Research Collaboration
Technical R&D Directions: Universal In Vivo CAR-T (Reducing Inter-Individual Variability), Smart Responsive Vectors (TME-Triggered Release), Multi-Target CAR Design (Preventing Tumor Escape)
Areas of Expansion: In Vivo CAR Therapy for Rare Diseases, Prophylactic CAR Engineering for Infectious Disease Prevention, and Exploratory Applications in Age-Related Diseases
Industry-Academia-Research Collaboration: A collaborative model involving academic institutions (breakthroughs in basic research), enterprises (industrialization process development), and medical institutions (clinical translation and validation), with core resource integration (sharing of technology platforms and alignment of clinical resources)
Module 11: R&D Case Review and Interactive Discussion
Deconstructing Typical R&D Cases: Preclinical Optimization of LNP-mRNA In Vivo CAR-T Therapy for Leukemia, and R&D Iteration of Biological Scaffolds in Breast Cancer Models
Interactive Workshop: Proposing Solutions Based on R&D Data for Issues Such as “Challenges in the Development of In Vivo CAR-T for Liver Cancer” and “Strategies for Long-Term Safety Validation of Non-Integrating Vectors”
Q&A and Exchange: Practical Issues of Concern to R&D Personnel, Including Technology Transfer, Patent Layout, and Capital Investment
To Every Key Decision-Maker and Core Practitioner Across the Upstream and Downstream of the Industry Chain
If you are:
R&D, quality, and clinical personnel, as well as corporate executives, from enterprises and research institutions that plan to develop in vivo CAR-T projects in the next 6–12 months
In vivo CAR-T-related delivery technology companies (LNP-mRNA delivery, lentiviral delivery, AAV delivery, etc.), viral vector and plasmid technology companies, CROs,
CDMO companies, third-party testing laboratories, instrument and equipment manufacturers, consumables and raw material suppliers, etc.
Entities currently conducting or planning to conduct in vivo CAR-T clinical trials (project sponsors, hospitals, clinical CROs, testing laboratories, safety assessment and toxicology companies,CMC Research Services Company)
Government agencies, universities and research institutes, hospitals, industrial parks, etc.
We cordially invite you to participate in this training session, where you will join industry experts in examining the key aspects of the entire In Vivo CAR-T process, from research and development to commercialization.
Elite Instructor Team
Mei Heng, Director of the Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Zhang Dan, Co-founder and Chief Strategy Officer of Kunling Pharma; Co-founder and Co-Chairman of Puxin Bio Jiang Hong, former Director of the Hubei Provincial Institute for Drug Control and Inspection, Professional Technical Level 2 Rao Chunming, Chief Scientist at Joinn Laboratories (China) Co., Ltd., former Director of the Recombinant Drugs Division and Senior Expert at the National Institutes for Food and Drug Control (NIFDC) Pu Jinhua, Former Team Leader of Biological Products Registration Inspectors at the Center for Food and Drug Inspection (CFDI), Senior Expert at Suzhou Institute for Drug Control Qi Fei, Executive Director at Legend Capital Yang Hanshuo, Founder of Zhenyu Bio, Professor at West China Hospital of Sichuan University Chen Zhengju, CEO of Better Biotech Hu Yong, Founder of Ruiji Biotech Ma Lijia, Ph.D. Supervisor at the Research Institute of Westlake University, Founder of Westlake Cloud Valley Intelligent Drug Science Qi Changsong, Associate Chief Physician and Associate Professor, Phase I Clinical Ward, Peking University Cancer Hospital Li Hongjian, Founder of Puruijin Wang Lijun, CEO of Xingcheng Bio
More instructors to be updated......
Training Registration
